Comparative evaluation of Western Blotting in hepatic and pulmonary cystic echinococcosis

WOS: 000244162600009PubMed ID: 17285854Many serological tests ore widely used in the diagnosis of cystic echinococcosis CE), caused by the larval stages of Echinococcus granulosus. The present study was carried for differentiation between hepatic and pulmonary cystic echinococcosis by Western Blotting (WB). A total of 12 1 sera from patients with hepatic CE (37, pulmonary CE (3 1) and controls 5 3; consisting of six healthy, seven Hymenolepis nono infection, 20 hepatic and 20 pulmonary diseases other than CE) were examined. In all of the CE patients, E. granulosus infection was confirmed by surgical intervention. Sera were previously tested using IHA and ELISA to detect the E. granulosus specific antibodies. Sera from hepatic cases of CE reacted with 16 polypeptides of 6-116 kDa and sera from pulmonary cases of CE reacted with 14 polypeptides of 4-130 kDa by Western Blotting. The WB test enabled the detection of antibodies in the hepatic CF samples for proteins of 24, 32 34, 44-46 and 52-54 kDa in molecular weight in 78.4%, 75.7%, 78.4% and 89,2 % of the patients, respectively. In the pulmonary CF samples sera WB test enabled the detection of antibodies 24, 44-46, 100, 1 10, 1 16 and 120-124 kDo in molecular weight in 81.3 %, 75.0 %, 87.5 %, 71.9 %, 84.4 % and 65.6 % of the patients, respectively. We indicated that the antigenic components of high molecular weight con be good candidates for differentiation of hepatic CF from pulmonary CF

Comparative evaluation of western blotting in hepatic and pulmonary cystic echinococcosis

WOS: 000244162600009PubMed ID: 17285854Many serological tests ore widely used in the diagnosis of cystic echinococcosis CE), caused by the larval stages of Echinococcus granulosus. The present study was carried for differentiation between hepatic and pulmonary cystic echinococcosis by Western Blotting (WB). A total of 12 1 sera from patients with hepatic CE (37, pulmonary CE (3 1) and controls 5 3; consisting of six healthy, seven Hymenolepis nono infection, 20 hepatic and 20 pulmonary diseases other than CE) were examined. In all of the CE patients, E. granulosus infection was confirmed by surgical intervention. Sera were previously tested using IHA and ELISA to detect the E. granulosus specific antibodies. Sera from hepatic cases of CE reacted with 16 polypeptides of 6-116 kDa and sera from pulmonary cases of CE reacted with 14 polypeptides of 4-130 kDa by Western Blotting. The WB test enabled the detection of antibodies in the hepatic CF samples for proteins of 24, 32 34, 44-46 and 52-54 kDa in molecular weight in 78.4%, 75.7%, 78.4% and 89,2 % of the patients, respectively. In the pulmonary CF samples sera WB test enabled the detection of antibodies 24, 44-46, 100, 1 10, 1 16 and 120-124 kDo in molecular weight in 81.3 %, 75.0 %, 87.5 %, 71.9 %, 84.4 % and 65.6 % of the patients, respectively. We indicated that the antigenic components of high molecular weight con be good candidates for differentiation of hepatic CF from pulmonary CF

Pres-Final-2204: Developing Of A New Scale For Assessing The Adherence To Colchicines Treatment In Pediatric Patients With Fmf

PubMe

Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish children

PubMed ID: 26393894Objective. To develop and assess the validity and reliability of an adherence scale concerning medical treatment in paediatric FMF patients. Methods. The Medication Adherence Scale in FMF Patients (MASIF) is a 18-item questionnaire that evaluates adherence to medication in four domains. Validation of the instrument was accomplished in paediatric FMF patients (aged 2-18 years) under medication at least for 6 months. The first step was to build up the scale through qualitative approach (with interviews using semi-structured questions). Validation analyses included assessment of feasibility, face and content validity; construct validity, internal consistency and test-retest reliability. Results. One hundred and fifty patients with FMF were enrolled in the study. The mean age of the patients was 11.11±4.02 years and 48.7% of them were male. The MASIF was found to be feasible and valid for both face and content. It correlated with the Morisky Medication Adherence Scale as a gold standard thereby demonstrating good construct validity (r=0.515, p < 0.001). Assessment of content validity identified four subscales. The internal consistency, Cronbach's alpha was 0.728. There was a positive and significant correlation between test and retest scores (r=0.843; p < 0.001). Also, a significant correlation between parents' and children's reports (r=0.781, p < 0.001). Conclusion. Based on these results, the use of this scale to assess and follow up the adherence to treatment in paediatric FMF patients under medical treatment is recommended. © Clinical and Experimental Rheumatology 2015

fever (MASIF) in a cohort of Turkish children

Objective. To develop and assess the validity and reliability of an adherence scale concerning medical treatment in paediatric FMF patients.Methods. The Medication Adherence Scale in FMF Patients (MASIF) is a 18-item questionnaire that evaluates adherence to medication in four domains. Validation of the instrument was accomplished in paediatric FMF patients (aged 2-18 years) under medication at least for 6 months. The first step was to build up the scale through qualitative approach (with interviews using semi-structured questions). Validation analyses included assessment of feasibility, face and content validity; construct validity, internal consistency and test-retest reliability.Results. One hundred and fifty patients with FMF were enrolled in the study. The mean age of the patients was 11.11 +/- 4.02 years and 48.7% of them were male. The MASIF was found to be feasible and valid for both face and content. It correlated with the Morisky Medication Adherence Scale as a gold standard thereby demonstrating good construct validity (r=0.5 15, p<0.001). Assessment of content validity identified four subscales. The internal consistency, Cronbach's alpha was 0.728. There was a positive and significant correlation between test and retest scores (r-0.843; p<0.001). Also, a significant correlation between parents' and children's reports (r=0.781, p<0.001).Conclusion. Based on these results, the use of this scale to assess and follow up the adherence to treatment in paediatric FMF patients under medical treatment is recommended

Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish children.

OBJECTIVES: To develop and assess the validity and reliability of an adherence scale concerning medical treatment in paediatric FMF patients. METHODS: The Medication Adherence Scale in FMF Patients (MASIF) is a 18-item questionnaire that evaluates adherence to medication in four domains. Validation of the instrument was accomplished in paediatric FMF patients (aged 2-18 years) under medication at least for 6 months. The first step was to build up the scale through qualitative approach (with interviews using semi-structured questions). Validation analyses included assessment of feasibility, face and content validity; construct validity, internal consistency and test-retest reliability. RESULTS: One hundred and fifty patients with FMF were enrolled in the study. The mean age of the patients was 11.11±4.02 years and 48.7% of them were male. The MASIF was found to be feasible and valid for both face and content. It correlated with the Morisky Medication Adherence Scale as a gold standard thereby demonstrating good construct validity (r=0.515, p<0.001). Assessment of content validity identified four subscales. The internal consistency, Cronbach's alpha was 0.728. There was a positive and significant correlation between test and retest scores (r=0.843; p<0.001). Also, a significant correlation between parents' and children's reports (r=0.781, p<0.001). CONCLUSIONS: Based on these results, the use of this scale to assess and follow up the adherence to treatment in paediatric FMF patients under medical treatment is recommended